A Phase 1/2 and Biomarker Study of Preoperative Short Course Chemoradiation With Proton Beam Therapy and Capecitabine Followed By Early Surgery for Resectable Pancreatic Ductal Adenocarcinoma

作者：Hong Theodore S^*; Ryan David P; Borger Darrell R; Blaszkowsky Lawrence S; Yeap Beow Y; Ancukiewicz Marek; Deshpande Vikram; Shinagare Shweta; Wo Jennifer Y; Boucher Yves; Wadlow Raymond C; Kwak Eunice L; Allen Jill N; Clark Jeffrey W; Zhu Andrew X; Ferrone Cristina R; Mamon Harvey J; Adams Judith; Winrich Barbara; Grillo Tarin; Jain Rakesh K; DeLaney Thomas F; Fernandez del Castillo Carlos; Duda Dan G

来源：International Journal of Radiation Oncology, Biology, Physics, 2014, 89(4): 830-838.

DOI：10.1016/j.ijrobp.2014.03.034

Purpose: To evaluate the safety, efficacy and biomarkers of short-course proton beam radiation and capecitabine, followed by pancreaticoduodenectomy in a phase 1/2 study in pancreatic ductal adenocarcinoma (PDAC) patients.
Methods and Materials: Patients with radiographically resectable, biopsy-proven PDAC were treated with neoadjuvant short-course (2-week) proton-based radiation with capecitabine, followed by surgery and adjuvant gemcitabine. The primary objective was to demonstrate a rate of toxicity grade >= 3 of <20%. Exploratory biomarker studies were performed using surgical specimen tissues and peripheral blood.
Results: The phase 2 dose was established at 5 daily doses of 5 GyE. Fifty patients were enrolled, of whom 35 patients were treated in the phase 2 portion. There were no grade 4 or 5 toxicities, and only 2 of 35 patients (4.1%) experienced a grade 3 toxicity event (chest wall pain grade 1, colitis grade 1). Of 48 patients eligible for analysis, 37 underwent pancreaticoduodenectomy. Thirty of 37 (81%) had positive nodes. Locoregional failure occurred in 6 of 37 resected patients (16.2%), and distant recurrence occurred in 35 of 48 patients (72.9%). With median follow-up of 38 months, the median progression-free survival for the entire group was 10 months, and overall survival was 17 months. Biomarker studies showed significant associations between worse survival outcomes and the KRAS point mutation change from glycine to aspartic acid at position 12, stromal CXCR7 expression, and circulating biomarkers CEA, CA19-9, and HGF (all, P<.05).
Conclusions: This study met the primary endpoint by showing a rate of 4.1% grade 3 toxicity for neoadjuvant short-course proton-based chemoradiation. Treatment was associated with favorable local control. In exploratory analyses, KRAS(G12D) status and high CXCR7 expression and circulating CEA, CA19-9, and HGF levels were associated with poor survival.

• 出版日期2014-7-15